Sinteza i farmakološko ispitivanje novih 4-(3-etilfenil)-1-supstituiranih 4H-[1,2,4]triazolo[4,3-a]kinazolin-5-ona kao nove klase H1-antihistaminika by VEERACHAMY ALAGARSAMY et al.
The first generation antihistamines penetrate the blood brain barrier and also pos-
sess anticholinergic properties; this has led to the development of a second generation of
H1-antagonists such as terfenadine, cetirizine and astemizole (1). A common feature of
the first generation compounds includes two aryl or heteroaryl rings linked to an ali-
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A series of novel 4-(3-ethylphenyl)-1-substituted-4H-[1,2,4]
triazolo[4,3-a]quinazolin-5-ones (4a-j) were synthesized
by the cyclization of 3-(3-ethylphenyl)-2-hydrazino-3H-
-quinazolin-4-one (3) with various one-carbon donors.
The starting material, compound 3, was synthesized from
3-ethyl aniline by a new innovative route with improved
yield. When tested for their in vivo H1-antihistaminic ac-
tivity on conscious guinea pigs, all test compounds pro-
tected the animals from histamine induced bronchospasm
significantly. Compound 4-(3-ethylphenyl)-1-methyl-4H -
-[1,2,4]triazolo[4,3-a]quinazolin-5-one (4b) emerged as the
most active compound of the series and it is more potent
(74.6 % protection) compared to the reference standard
chlorpheniramine maleate (71 % protection). Compound
4b shows negligible sedation (10 %) compared to chlor-
pheniramine maleate (30 %). Therefore compound 4b can
serve as the leading compound for further development
of a new class of H1-antihistamines.
Keywords: quinazolin-5-ones, sedation, H1-antihistaminic
agents
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phatic tertiary amine via the side chain (diphenhydramine and pheniramine) (2). The se-
cond generation compounds (terfenadine and cetirizine) contain many of the structural
features of the first generation compounds. The real breakthrough of non-sedative anti-
histamines came in the early eighties of the twentieth century when modern antihista-
mines were found to exhibit potent antihistaminic activity without sedative effect (3).
Condensed heterocycles containing the new generation of H1-antihistamines (loratadi-
ne, azelastine and flazelastine) that do not possess the above mentioned pharmacophore
for H1-antihistamines paved the way for the discovery of many novel antihistamines,
temelastine (4) and mangostin (5). Quinazolines and condensed quinazolines show ex-
cellent antihistaminic activity (6, 7). In continuation, we demonstrated (8, 9) the quina-
zoline derivatives as potent antihistamines with the least sedation. The present work is
an extension of our ongoing efforts towards development and identification of new mole-
cules. Therefore we undertook to synthesize a series of 1,2,4-triazolo-4H-[4,3-a]quina-
zolin-5-ones containing 3-ethylphenyl substituted at position 4 and alkyl/alicyclic ami-
nes substituted at position 1. The synthesized compounds were tested for their in vivo
H1-antihistaminic activity on conscious guinea pigs. As sedation is one of the major side
effects associated with antihistamines, the test compounds were also evaluated for their
sedative potentials by measuring the reduction in locomotor activity using an actopho-
tometer.
EXPERIMENTAL
Melting points were taken in open capillaries on a Thomas Hoover melting point
apparatus (Thomas Hoover, USA) and are uncorrected. IR spectra were recorded in film
or in potassium bromide disks on a Perkin-Elmer 398 spectrometer (Perkin-Elmer, USA).
1H spectra were recorded on a DPX-300 MHz Bruker FT-NMR spectrometer (Bruker, USA).
Chemical shifts were reported as parts per million (d ppm) using tetramethylsilane (TMS)
as an internal standard. Mass spectra were obtained on a Jeol-SX-102 instrument (Jeol,
Japan) using fast atom bombardment (FAB positive). Elemental analysis was performed
on a Perkin-Elmer 2400 CHN analyzer (Perkin-Elmer, USA); the values were found within
the acceptable limits of the calculated values (± 0.4 %). Spectral data (IR, NMR and mass
spectra) and elemental analysis data are presented in Tables I and II. The progress of the
reaction was monitored on ready-made silica gel plates (Merck, Norway) using chloro-
form/methanol (9:1) as a solvent system. Iodine was used as a developing agent. All chemi-
cals and reagents used in the syntheses were obtained from Aldrich (USA), Lancaster
(USA) or Spectrochem (India). They were used without further purification.
Syntheses
3-(3-Ethylphenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one (1). – A solution of 3-ethyl
aniline (0.02 mol) in dimethyl sulfoxide (10 mL) was stirred vigorously. To this, carbon-
disulphide (1.6 mL) and aqueous sodium hydroxide 1.2 mL (2 mol L–1) were added drop-
wise during 30 min under stirring. Dimethyl sulfate (0.02 mol) was added gradually keep-
ing the reaction mixture stirred for 2 h. The reaction mixture was then poured into ice
water. The solid obtained was filtered, washed with water, dried and recrystallized from
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ethanol. Methyl anthranilate (0.01 mol) and the prepared N-(3-ethylphenyl)-methyl di-
thiocarbamic acid (0.01 mol) were dissolved in ethanol (20 mL). To this, anhydrous po-
tassium carbonate (100 mg) was added and refluxed for 23 h. The reaction mixture was
cooled in ice and the solid separated was filtered and purified by dissolving in 10 % al-
coholic sodium hydroxide solution and reprecipitated by treating with dilute hydrochloric
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acid. The solid obtained was filtered, washed with water, dried and recrystallized from
ethanol.
3-(3-Ethylphenyl)-2-methylsulfanyl-3H-quinazolin-4-one (2). – Compound 1 (0.01 mol)
was dissolved in 40 mL of 2 % alcoholic sodium hydroxide solution. To this, dimethyl
sulfate (0.01 mol) was added dropwise under stirring. The stirring was continued for 1 h,
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Table II. IR and NMR spectral data of intermediate and newly synthesized compounds
Compd.
IR (KBr) (cm–1)
1H NMR (CDCl3), d (ppm)
C=O C=N
1 1692 –a 1.52–1.64 (t, 3H, CH2CH3), 2.43–2.56 (q, 2H, CH2CH3), 7.15–7.79
(m, 8H, ArH), 10.45 (br s, 1H, NH, D2O exchangeable)
2 1692 –a 1.25–1.38 (t, 3H, CH2CH3), 2.05–2.17 (q, 2H, CH2CH3), 2.46
(s, 3H, SCH3), 7.33–8.05 (m, 8H ArH)
3 1680 –a 1.33–1.45 (t, 3H, CH2CH3), 2.75–2.89 (q, 2H, CH2CH3) 5.02 (br s, 2H,
NH2 D2O exchangeable), 7.11–7.79 (m, 8H, ArH), 9.53 (br s, 1H, NH
D2O exchangeable)
4a 1.01–1.15 (t, 3H, CH2CH3), 2.13–2.26 (q, 2H, CH2CH3), 7.01–7.35
(m, 4H, ArH), 7.54 (s, 1H, ArH), 7.73–8.05 (m, 4H, ArH)
4b 1680 1610 1.23 (s, 3H, CH3), 1.42–1.51 (t, 3H, CH2CH3), 2.85–2.97
(q, 2H, CH2CH3), 7.14–7.63 (m, 8H, ArH)
4c 1678 1604 1.13–1.24 (t, 3H, CH2CH3), 1.44–1.54 (t, 3H, CH2CH3), 2.21–2.33
(q, 3H, CH2CH3), 2.62–2.75 (q, 2H, CH2CH3), 7.05–7.65 (m, 8H, ArH)
4d 1681 1612 0.65–0.73 (t, 2H, CH2CH2CH3), 1.08–1.15 (sext, 2H, CH2CH2CH3),
1.34–1.45 (q, 2H, CH2CH3), 2.42–2.55 (t, 3H, CH2CH3), 2.83–2.94
(t, 3H, CH2CH2CH3), 7.21–7.95 (m, 8H, ArH)
4e 1684 1616 1.04–1.15 (t, 3H, CH2CH3), 2.25–2.36 (q, 2H, CH2CH3), 3.15
(s, 2H, CH2), 7.05–7.66 (m, 8H, ArH)
4f 1680 1610 1.01–1.25 (m, 4H, CH2-pyrrolidinyl), 1.43–1.64 (m, 4H,
CH2-pyrrolidinyl), 2.43–2.51 (t, 3H, CH2CH3), 2.72–2.83
(q, 3H, CH2CH3), 3.65 (s, 2H, CH2), 7.22–7.84 (m, 8H, ArH)
4g 1690 1615 0.89–1.09 (m, 6H, CH2-piperidyl), 1.42–1.65 (m, 4H, CH2-piperidyl),
2.33–2.45 (t, 3H, CH2CH3), 2.63–2.78 (q, 2H, CH2CH3), 3.45
(s, 2H, CH2), 7.35–7.76 (m, 8H, ArH)
4h 1670 1612 1.21–1.42 (m, 4H, CH2-morpholinyl), 1.75–1.85 (m, 4H,
CH2-morpholinyl), 2.13–2.25 (t, 3H, CH2CH3), 2.51–2.64
(q, 2H, CH2CH3), 3.35 (s, 2H, CH2), 7.11–7.75 (m, 8H, ArH)
4i 1691 1610 0.95–1.13 (m, 4H, CH2-piperazinyl), 1.45–1.66 (m, 4H,
CH2-piperazinyl), 2.03–2.15 (t, 3H, CH2CH3), 2.63–2.75
(q, 2H, CH2CH3), 3.75 (s, 2H, CH2), 7.35–7.89 (m, 8H, ArH), 9.57
(s, 1H, NH, D2O exchangeable)
4j 1686 1602 1.01–1.25 (m, 4H, CH2-piperazinyl), 1.44–1.65 (m, 4H,
CH2-piperazinyl), 2.11–2.36 (t, 3H, CH2CH3), 2.52–2.66 (q, 2H,
CH2CH3), 3.05 (s, 3H, CH3), 3.26 (s, 2H, CH2), 7.34–7.87 (m, 8H, ArH)
a Not applicable
the reaction mixture was then poured into ice water. The solid obtained was filtered,
washed with water, dried and recrystallized from the ethanol/chloroform (75:25) mixture.
3-(3-Ethylphenyl)-2-hydrazino-3H-quinazolin-4-one (3). – Compound 2 (0.01 mol) was
dissolved in ethanol (25 mL). To this, hydrazine hydrate (99 %) (0.1 mol) and anhydrous
potassium carbonate (100 mg) were added and refluxed for 38 h. The reaction mixture
was cooled and poured into ice water. The solid so obtained was filtered, washed with
water, dried and recrystallized from the chloroform/benzene (25:75) mixture.
4-(3-Ethylphenyl)-1-subtituted-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-ones (4a-e). – 3-(4-Et-
hylphenyl)-2-hydrazino-3H-quinazolin-4-one (3) (0.01 mol) and formic acid (25 mL) were
print in a round-bottomed flask and refluxed for 36 h, cooled and poured into ice water.
The solid obtained 4a was filtered, washed with water, dried and recrystallized from etha-
nol. Adopting this procedure, compounds 4b-e were also prepared.
4-(3-Ethylphenyl)-1-subtituted-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one (4f-j). – A mixture
of 1-chloromethyl-4-(3-ethylphenyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one (4e) (0.01 mol)
pyrrolidine (0.05 mol) and anhydrous potassium carbonate (100 mg) in dioxane (25 mL)
was put in a round bottomed flask and refluxed for 39 h, cooled and poured into ice wa-
ter. The solid obtained 4f was filtered, washed with water, dried and recrystallized from
ethanol/benzene (50:50). Implementing this protocol, compounds 4g-j were also prepared.
Pharmacology
Animals. – Antihistaminic activity was evaluated on male Dunkin Hartley guinea
pigs (250–300 g), while sedative-hypnotic activity was tested on albino Swiss mice. The
animals were maintained in colony cages at 25 ± 2 C, relative humidity of 45–55 %, un-
der a 12 h light and dark cycle; they were fed standard animal feed. All animals were ac-
climatized for a week before the experiment. The Institutional Animal Ethics Committee
approved the protocol adopted for the experimentation on animals.
Antihistaminic activity. – A modification of the method of Van Arman (10) was adop-
ted to determine the antihistaminic potential of the synthesized compounds. Six animals
were alloted to each group and were fasted for 12 h. The test compounds and reference
standard (chlorpheniramine maleate) were administered orally at a dose of 10 mg kg–1 in
1 % CMC (carboxymethylcelluose) and challenged with histamine aerosol (3 mL of 0.2 %
aqueous solution of histamine hydrochloride) in a vaponephrin pocket nebulizer spra-
yed into a closed transparent cage. The respiratory status reflecting the increasing de-
gree of bronchoconstriction was recorded. The time for the onset of convulsions (precon-
vulsion) was recorded. Animals remaining stable for more than 6 min were considered
protected against histamine-induced bronchospasm. An intraperitoneal injection of chlor-
pheniramine maleate (Avil, India) at a dose of 25 mg kg–1 was given for the recovery of
test animals.
Sedative-hypnotic activity. – Sedative-hypnotic activity was determined by measuring
the reduction in locomotor activity using an actophotometer (11, 12). Six albino Swiss
mice were allotted to each group. Basal activity score was taken and then compounds
4a-j and standard chlorpheniramine maleate were administered orally at a dose of 5 mg
kg–1 in 1 % CMC. Scores were recorded 1, 2 and 3 h after the drug administration.
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Statistical analysis. – Statistical analysis of the biological activity of the synthesized
compounds on animals was evaluated using a one-way analysis of variance (ANOVA).
In all cases, posthoc comparisons of the means of individual groups were performed us-
ing Tukey’s test. All values are expressed as mean ± SD (standard deviation). For statisti-
cal analysis, the GraphPad Prism 3.0 version was used.
RESULTS AND DISCUSSION
Chemistry
The key intermediate 3-(3-ethylphenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one (1)
was prepared by refluxing methyl anthranilate with 3-ethylphenyl isothiocyanate in eth-
anol. However, the preparation of 3-ethylphenyl isothiocyanate required for the reaction
was a tedious, time consuming process and the yield was also low (60 %). An alternate
route was attempted to synthesize compound 1. In this route, 3-ethyl aniline was reacted
with carbon disulphide and anhydrous potassium carbonate in acetone to give potas-
sium dithiocarbamate, which was methylated with dimethyl sulfate to afford the dithio-
carbamic acid methyl ester, which was refluxed with methyl anthranilate to yield 1. This
way of synthesizing 1 suffers from the drawbacks such as the multi-step process, pro-
longed reaction time (37 h) and low yield (30 %). Hence, improvisation was carried out
in this method by using aqueous sodium hydroxide (2 mol L–1) instead of anhydrous
K2CO3, and dimethyl sulphoxide (DMSO) (Scheme 1) as a solvent instead of acetone.
The use of DMSO as the reaction solvent enhanced the rate of reaction and the use of al-
kali in higher concentration helped prevent hydrolysis of the intermediate, probably due
to less solvation. These modifications not only curtailed the reaction time from 37 to 25 h,
but also increased the yield from 30 to 80 %. The product obtained was cyclic and not
open-chain thiourea. The structure was confirmed by the IR spectrum, which showed in-
tense peaks at 3216 cm–1 for cyclic thiourea (NH), 1692 cm–1 for carbonyl (C=O) and 1210
cm–1 for thioxo (C=S) stretching. 1H NMR spectrum of 1 showed a triplet at d 1.52–1.64
ppm due to the CH3 group, a quartet at d 2.43–2.56 ppm due to CH2 and a multiplet at d
7.15–7.79 ppm for aromatic (8H) protons and a singlet at d 10.45 ppm indicating the pre-
sence of NH. Data from the elemental analyses were found to be in conformity with the
assigned structure. Further, the molecular ions recorded in the mass spectrum are also in
agreement with the molecular mass of compound 1.
3-(3-Ethylphenyl)-2-methysulfanyl-3H-quinazolin-4-one (2) was obtained by dissol-
ving product 1 in a 2 % alcoholic sodium hydroxide solution and methylating with di-
methyl sulfate while stirring at room temperature. The IR spectrum of 2 showed disap-
pearance of NH and C=S stretching signals of cyclic thiourea. It showed a peak for car-
bonyl (C=O) stretching at 1692 cm–1. The 1H NMR spectrum of compound 2 showed a
triplet at d 1.25–1.38 ppm due to CH3, a quartet at d 2.05–2.17 ppm due to CH2, a singlet
at d 2.46 ppm due to SCH3 and a multiplet at d 7.33–8.05 ppm due to aromatic (8H) pro-
tons. Data from the elemental analyses and the molecular ion recorded in the mass spec-
trum further confirmed the assigned structure of 2.
Nucleophilic displacement of methylthio group of compound 2 with hydrazine hy-
drate was carried out using ethanol as solvent to afford 3-(3-ethylphenyl)-2-hydrazino-
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-3H-quinazolin-4-one (3). The required long duration of the reaction (38 h) might be due
to the presence of the bulky aromatic ring at position 3, which might have reduced the
reactivity of the quinazoline ring system at C-2 position. The formation of 3 was con-
firmed by the presence of NH and NH2 signals at 3390–3225 cm–1 in the IR spectrum. It
also showed a peak for carbonyl (C=O) at 1680 cm–1. The 1H NMR spectrum of com-
pound 3 showed singlets at d 2.46 ppm due to SCH3, a triplet at d 1.33–1.45 ppm due to
CH3 group, a quartet at d 2.75–2.89 due to CH2, singlets at d 5.02 ppm and 9.53 ppm due
to NH2 and NH respectively, a multiplet at d 7.11–7.77 ppm for aromatic (8H) protons.
Data from the elemental analyses were found to be in conformity with the assigned stru-
cture of 3. Further, the molecular ion recorded in the mass spectrum is also in agreement
with the molecular mass of compound 3.
The title compounds were synthesized by cyclization of 3-(3-ethylphenyl)-2-hydra-
zino-3H-quinazolin-4-one (3) with various one-carbon donors. The 3-(3-ethylphenyl)-2-hy-
drazino-3H-quinazolin-4-one was synthesized from 3-ethyl aniline by a new innovative
route (Scheme 1). The title compounds 4a-j were obtained in fair to good yields through
cyclization of 3 with a variety of one-carbon donors such as formic acid, acetic acid, pro-
pionic acid, butyric acid and chloroacetyl chloride at reflux. The cyclic product forma-
tion is indicated by the disappearance of peaks due to NH and NH2 of the starting com-
pound at 3390–3225 cm–1 in IR spectra of all compounds 4a-e. The 1H NMR spectra of
4f-j showed the absence of NH and NH2 signals. Compounds 4f-j were obtained by the
displacement of chlorine of compound 4e with various alicyclic amines such as pyrro-
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lidine, piperidine, morpholine, piperazine and 4-methylpiperazine. The IR spectra of com-
pounds 4a-j showed a peak for carbonyl (C=O) around 1680 cm–1. The 1H NMR spectra
of compounds 4a-j showed multiplets around d 7.01–8.09 ppm integrating for aromatic
protons. Mass spectra of the title compounds are in conformity with the assigned struc-
ture and showed molecular ion peaks corresponding to their molecular formula. The
M++2 peak was observed in the spectrum of compound 4e, confirming the presence of
the chlorine atom in the compound. The relative intensity of this M++2 peak compared
to M+ peak is in a ratio of 1:3. The M++2 peak observed in the spectrum of compound 4e
disappeared in compounds 4f-j, confirming the displacement of chlorine. In mass spec-
tra of compounds 4a-j, the peak due to 1,2,4-triazolo[4,3-a]quinazoline cation appeared
at m/z 168. In addition, a common peak at m/z 144 corresponding to quinazolin-4-one
moiety appeared in all mass spectra. Elemental analyses confirmed the elemental com-
position and purity of the synthesized compounds.
Pharmacology
Compounds containing the 1,4-disubstituted [1,2,4]triazoloquinazoline ring system
(4a-j) were evaluated for their in vivo antihistaminic activity. All the tested compounds
were found to exhibit good antihistaminic activity (Table III). Protection data showed
that all compounds of the series show significant protection in the range of 70–74 %. Bio-
logical studies indicated that different substituents over the first position of the triazo-
loquinazoline ring exerted varying biological activity. The presence of the methyl group
(compound 4b, 74.6 % protection) showed better activity than the unsubstituted com-
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Table III. Antihistaminic and sedative-hypnotic activity of compounds 4a-j
Compd.





1 h 2 h 3 h
Controlc 116 ± 2d – 6 ± 1d 4 ± 1d 4 ± 1d
Chlorpheniramine 400 ± 10 71 ± 1 37 ± 2 32 ± 2 22 ± 2d
4a 415 ± 2f 72 ± 2 8 ± 1d 12 ± 1d 6 ± 2d
4b 456 ± 3d 75 ± 2e 9 ± 2d 13 ± 2d 9 ± 1d
4c 445 ± 9e 74 ± 1e 11 ± 2d 15 ± 2d 7 ± 2d
4d 398 ± 7 71 ± 2 14 ± 2d 17 ± 2d 9 ± 2d
4e 390 ± 7f 70 ± 1f 6 ± 2d 12 ± 2d 6 ± 2d
4f 395 ± 7 71 ± 1f 8 ± 2d 10 ± 1d 8 ± 2d
4g 403 ± 8 71 ± 2 10 ± 2d 11 ± 2d 7 ± 2d
4h 409 ± 7 72 ± 2 11 ± 2d 13 ± 1d 9 ± 1d
4i 426 ± 6e 73 ± 2f 10 ± 1d 14 ± 2d 8 ± 1d
4j 438 ± 5d 74 ± 2f 13 ± 2d 12 ± 2d 8 ± 1d
a Control: oral dose of 10 mg kg–1 in 1 % CMC.
b Control: oral dose of 5 mg kg–1 in 1 % CMC.
c Control: animals were administered 1 % CMC orally.
Significant different relative to chlorpheniramine: d p < 0.0001, e p < 0.001, f p < 0.01.
pound (compound 4a, 72.0 % protection). With increased lipophilicity (i.e., ethyl com-
pound 4c, 73.9 % protection) the activity remained but further increase in lipophilicity
(i.e., propyl compound 4d, 70.8 % protection) led to a decrease in activity. Replacement
of a proton of the methyl group by chlorine (compound 4e, 70.2 % protection) showed a
further decrease in activity. Replacement of a proton of the methyl group by alicyclic
amines (pyrrolidinyl and piperidinyl compound 4f 70.6 % protection and 4g 71.2 % pro-
tection, respectively) showed an increase in activity compared to the chloro substituent.
Placement of alicyclic amines with additional hetero atom (morpholinyl compound 4h
71.6 % protection; piperazinyl compound 4i 72.8 % protection and 4-methyl piperazinyl
compound 4j 73.5 % protection) led to further increase in activity. As the test compounds
could not be converted to water-soluble form, in vitro evaluation for antihistaminic acti-
vity could not be performed.
The results of sedative-hypnotic activity indicate that all the test compounds exhi-
bited negligible sedation (8–13 %) whereas the reference standard chlorpheniramine ma-
leate showed 30 % sedation.
CONCLUSIONS
The present study describes the synthesis of a new series of 4-(3-ethylphenyl)-1-sub-
stituted-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-ones (4a-j). The title compounds have exhi-
bited promising antihistaminic activity against histamine-induced bronchospasm on con-
scious guinea pigs in the in vivo model. Among the series, 4-(3-ethylphenyl)-1-methyl-4H-
-[1,2,4]triazolo[4,3-a]quinazolin-5-one (4b) was found to be the most active compound. It
was more potent than the reference standard chlorpheniramine maleate. Interestingly,
compound 4b also showed negligible sedation and could therefore serve as a lead mole-
cule for further modifications to obtain a clinically useful novel class of non-sedating an-
tihistamines.
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S A @ E T A K
Sinteza i farmakolo{ko ispitivanje novih 4-(3-etilfenil)-1-supstituiranih
4H-[1,2,4]triazolo [4,3-a]kinazolin-5-ona kao nove klase H1-antihistaminika
VEERACHAMY ALAGARSAMY, KUNCHU KAVITHA, MANI RUPESHKUMAR, VISWAS RAJA SOLOMON, JAYA KUMAR,
DINAKARAN SATHESH KUMAR i HEMANT KUMAR SHARMA
Ciklizacijom 3-(3-etilfenil)-2-hidrazino-3H-kinazolin-4-ona (3) s razli~itim donorima
jednog C atoma sintetizirana je serija novih 4-(3-etilfenil)-1-supstituiranih 4H-[1,2,4]tria-
zolo[4,3-a]kinazolin-5-ona (4a-j). Po~etni spoj 3 pripravljen je iz 3-etil anilina na novi, ino-
vativni na~in, s pobolj{anim iskori{tenjem. U testovima in vivo na zamorcima, svi testi-
rani spojevi pokazali su zna~ajno za{titno djelovanje protiv bronhospazma induciranog
histaminom. Spoj 4-(3-etilfenil)-1-metil-4H-[1,2,4]triazolo[4,3-a]kinazolin-5-on (4b) najaktiv-
niji je me|u testiranim spojevima (za{tita 74.6 %) i ja~i od referentnog standarda klor-
feniramin maleata (za{tita 71 %). Spoj 4b pokazuje zanemarivu sedaciju (10 %) u usporedbi
s klorfeniramin maleatom (30 %). Stoga spoj 4b mo`e biti vode}i spoj za daljnji razvoj
nove klase H1-antihistaminika.
Klju~ne rije~i: kinazolin-5-oni, sedacija, H1-antihistaminici
Medicinal Chemistry Research Laboratory, MNR College of Pharmacy, Fasalwadi, Sangareddy-502294, India
Bharathi College of Pharmacy, Bharathi Nagar, K. M. Doddi-571422, Mandya (Dist), India
Medicinal & Process Chemistry Division, Central Drug Research Institute, Lucknow-226001, India
Department of Pharmaceutical Chemistry, Nalanda College of Pharmacy Cheralpally, Nalgonda-508001, India
Department of Pharmaceutical Chemistry, Patel College of Pharmacy, Bhopal, India
106
V. Alagarsamy et al.: Synthesis and pharmacological investigation of novel 4-(3-ethylphenyl)-1-substituted-4H-[1,2,4]triazolo[4,3-a]
quinazolin-5-ones as a new class of H1-antihistaminic agents, Acta Pharm. 59 (2009) 97–106.
